0 items

in your cart
$0.00

Drug Search > Qvar

Prescription Drug Search

Strengths available for Qvar inhaler:

Qvar inhaler 50mcg
Qvar inhaler 100mcg

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about ExpressMedsCanada.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Qvar:

  • Austria
  • Bangladesh
  • Belize
  • Bolivia
  • Chile
  • Colombia
  • Croatia
  • Denmark
  • Ecuador
  • El Salvador
  • Georgia
  • Germany
  • Greece
  • Guadeloupe
  • Guatemala
  • Honduras
  • Hungary
  • Iceland
  • India
  • Iran
  • Japan
  • Korea, Republic of
  • Kuwait
  • Lebanon
  • Lithuania
  • Moldova, Republic of
  • Morocco
  • New Zealand
  • Paraguay
  • Portugal
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Seychelles
  • Slovenia
  • South Africa
  • Ukraine
  • United Kingdom, UK
  • United States, US
  • Uruguay
View All Countries

Latest news releases on Qvar:

Teva Pharma (TEVA) Sees Weaker FY12 Sales, EPS - StreetInsider.com

Brand product net sales of approximately $8.0 billion including estimated global net sales of the following products: COPAXONE of $3.8 billion-- TREANDA® of $580 million-- Women’s Health products of $500 million-- ProAir® HFA of $430 million-- QVAR ...

Teva Issues 2012 Outlook - Analyst Blog - NASDAQ

QVAR and Azilect are slated to post revenues of $350 million and $340 million, respectively. Finally, OTC sales are expected to be about $1 billion. Other net sales are also expected to be about $800 million. Teva expects to spend between 6.8% ...

Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40 - StreetInsider.com

COPAXONE® of $3.8 billion-- TREANDA® of $580 million-- Women’s Health products of $500 million-- ProAir® HFA of $430 million-- QVAR® of $350 million-- PROVIGIL® of $420 million-- AZILECT® of $340 million-- NUVIGIL® of $300 million -- OTC net sales ...

Teva Reports First Quarter 2012 Results - Business Wire

Respiratory products revenues were up 4% to $190 million, driven primarily by higher global sales of Qvar® that reached $63 million this quarter, partially off-set by lower sales of ProAir® due to the renegotiation of the distribution sales agreements in ...

Medicis Reports First Quarter 2012 Financial Results - msnbc.com

The Company acquired ZYCLARA and ALDARA in the fourth quarter of 2011. The Company acquired the MAXAIR AUTOHALER and QVAR (in Canada only) in the fourth quarter of 2011. The Medicis Other Non-Dermatological Products category includes primarily A ...

Customer Service
1-866-799-3435 - Use Discount Code 7500 | Contact Form
Copyright © 2012 ExpressMedsCanada.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK